Do I need to take ivonib (ivitinib) all the time?

Ivosidenib (Ivosidenib), as a cancer-targeted inhibitor targeting isocitrate dehydrogenase-1 (IDH1) mutations, treatment usually needs to be continued, but it is not necessary to take Ivosidenib all the time. Whether you need to continue taking ivonib depends mainly on the patient's specific condition, treatment response, and the doctor's professional advice.

First, ivosidenib is recommended for continued treatment until disease progression or until the patient cannot tolerate its toxicity. This means that treatment with ivosidenib should be continuous as long as the disease is effectively controlled and the drug is tolerated by the patient. For patients who do not experience disease progression or unacceptable toxicity, it is recommended to receive treatment for at least 6 months to fully observe their clinical response. This continuous treatment ensures a stable concentration of the drug in the body, thereby maintaining the inhibitory effect on cancer cells.

However, if the patient's disease progresses during treatment or the drug's toxic effects are intolerable, doctors may adjust the treatment plan, including discontinuing ivosidenib or switching to other treatments. In addition, even if ivonib treatment is effective, doctors may adjust the drug dosage or treatment cycle in a timely manner based on the patient's specific condition and treatment response.

In general, whether Ivonib needs to be taken all the time depends on the patient's specific condition and treatment response. Continued treatment is necessary when the disease is effectively controlled and the patient tolerates the medication. However, the doctor will adjust the individualized treatment plan according to the patient's actual situation to ensure the safety and effectiveness of the treatment. Therefore, patients should receive regular evaluation and guidance from doctors while taking ivonib to ensure the smooth progress of treatment.